Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancer

Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancer - Feasibility study of CBDCA+TS-1 adjuvant therapy for non-small cell lung cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009101

Enrollment

Registered

2012-10-12

Start date

2012-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

carcinostatics CBDCA, TS-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: p-stage IB(T2a>4cm)/II/IIIA non-small cell lung cancer complete resection with more than lobectomy PS 0-1 preserved bone marrow, liver, renal, lung function

Exclusion criteria

Exclusion criteria: Allergy for CBDCA/TS-1 Myocardial infarction within 6 months Interstitial pneumonia sever heart disease significant psychological disease uncontrollable diabetes mellitus

Design outcomes

Primary

Measure	Time frame
Accomplishment of 4 course treatment	—

Secondary

Measure	Time frame
safety, 2-year disease free survival, overall survival	—

Countries

Japan

Contacts

Public ContactMasayoshi Inoue

Osaka University Graduate School of Medicine Department of General Thoracic Surgery

mi@thoracic.med.osaka-u.ac.jp06-6879-3152

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026

Feasibility study of CBDCA+TS-1 adjuvant therapy for p-stage IB(T2a&gt;4cm)/II/IIIA non-small cell lung cancer